Next 10 |
2024-06-25 08:13:12 ET More on Takeda, Wave Life Sciences, etc. Takeda: Strong Growth Catalysts And Maturing Pipeline Continue To Limit Downside Risk Takeda Pharmaceutical Company Limited (TAK) Fiscal Year 2023 Earnings Call Transcript Wave Life Sciences Ltd. (WVE) Q...
Statistically significant, potent, and durable allele-selective silencing: 46% mean reduction in CSF mutant huntingtin (mHTT) protein compared to placebo, preservation of wild-type huntingtin (wtHTT) protein, and generally safe and well-tolerated profile achieved in 30 mg multidose cohort ...
Presentation at the Obesity & Weight Loss Drug Development Summit to review Real World Evidence for the GLP-1 class and the opportunity for Wave’s INHBE program as a best-in-class approach for obesity designed to induce fat burning and preserve muscle mass with once or twice-annual sub...
2024-06-07 15:09:58 ET More on Alnylam, Pliant, etc. Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2024 Earnings Call Transcript Alnylam Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation ...
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is...
2024-05-20 09:58:45 ET More on PTC Therapeutics PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts PTC Therapeutics, Inc. (PTCT) Q1 2024 Earnings Call Transcript PTC Therapeutics, Inc. (PTCT) Q4 2023 Earnings Call Transcript PTC Therapeuti...
2024-05-15 14:11:35 ET More on Wave Life Sciences Wave Life Sciences Ltd. (WVE) Q1 2024 Earnings Call Transcript Wave Life Sciences' Weighty Ambition: Carving Out Obesity Niche Wave Life Sciences Ltd. (WVE) Q4 2023 Earnings Call Transcript Wave Life Sciences ...
2024-05-15 07:00:05 ET Tiago Fauth from Wells Fargo issued a price target of $11.00 for WVE on 2024-05-15 05:53:00. The adjusted price target was set to $11.00. At the time of the announcement, WVE was trading at $5.84. WVE currently trades -24.58% versus its 52 week hig...
2024-05-09 18:44:45 ET More on Catalyst Pharmaceuticals, Sarepta Therapeutics, etc. Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2024 Earnings Call Transcript Sarepta Therapeutics, Inc. (SRPT) Q1 2024 Earnings Call Transcript Sarepta Therapeutics: Growth Trajectory Alter...
2024-05-09 14:53:01 ET Wave Life Sciences Ltd. (WVE) Q1 2024 Earnings Conference Call May 09, 2024 08:30 AM ET Company Participants Kate Rausch - Vice President, Investor Relations & Corporate Affairs Paul Bolno - President & Chief Executive Officer Anne-...
News, Short Squeeze, Breakout and More Instantly...
Wave Life Sciences Ltd. Company Name:
WVE Stock Symbol:
NASDAQ Market:
Statistically significant, potent, and durable allele-selective silencing: 46% mean reduction in CSF mutant huntingtin (mHTT) protein compared to placebo, preservation of wild-type huntingtin (wtHTT) protein, and generally safe and well-tolerated profile achieved in 30 mg multidose cohort ...
Presentation at the Obesity & Weight Loss Drug Development Summit to review Real World Evidence for the GLP-1 class and the opportunity for Wave’s INHBE program as a best-in-class approach for obesity designed to induce fat burning and preserve muscle mass with once or twice-annual sub...
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is...